Engineered immune cells take on tough childhood cancers
NCT ID NCT06064903
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new treatment called CD7-CART01 for children whose T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma has come back or not responded to standard therapy. The treatment uses the child's own immune cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD7. The trial will first find the safest dose and then check how well it works at shrinking the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD7-CART01 (a type of CAR T-cell therapy made from the patient's own immune cells, engineered to target CD7 on cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for children with hard-to-treat T-cell leukemia or lymphoma, potentially leading to remission.
- What could go wrong
- This is an early-phase trial with only 26 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Rome, 00165, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T therapy targets tough childhood blood cancers
- Stem cell showdown: which transplant best keeps T-Cell cancer at bay?
- New trial aims to boost survival in kids with rare lymphoma
- Promising combo for tough leukemia stalls: trial ends early
- New hope for tough leukemia: capivasertib combo enters human trials
- Texting to beat leukemia: study tests if phone reminders boost chemo adherence